
|Videos|August 30, 2021
Dr. Seth weighs in on onabotulinumtoxinA injections in patients with complex medical backgrounds
Author(s)Urology Times staff
“Botox to [the] bladder has, in some ways, changed the paradigm of treatment for [overactive bladder],” says Jai Seth, MD.
Advertisement
In this video, Jai Seth, MD, discusses the background and objectives of the Neurourology and Urodynamics study, “Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.” Seth is a consultant urological surgeon at St. George’s University hospital, London, UK.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants priority review to talazoparib plus enzalutamide for HRR gene-altered mCSPC
2
KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM
3
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
4
PTEN Loss in Metastatic Prostate Cancer: Biology and Prognosis
5











